Zacks Research Predicts Reduced Earnings for Haemonetics

Haemonetics Corporation (NYSE:HAE) – Equities researchers at Zacks Research dropped their Q3 2027 earnings per share (EPS) estimates for Haemonetics in a research report issued to clients and investors on Thursday, May 28th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings per share of $1.37 for the quarter, down from their previous forecast of $1.42. The consensus estimate for Haemonetics’ current full-year earnings is $5.23 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2027 earnings at $1.42 EPS, Q2 2028 earnings at $1.45 EPS and Q4 2028 earnings at $1.41 EPS.

A number of other analysts have also recently issued reports on HAE. Citigroup lifted their price objective on Haemonetics from $64.00 to $70.00 and gave the company a “neutral” rating in a research report on Thursday. Barrington Research reduced their price objective on Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research report on Tuesday, May 12th. Mizuho reduced their price objective on Haemonetics from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. JPMorgan Chase & Co. reduced their price objective on Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Finally, Weiss Ratings cut Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, May 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $77.11.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $67.37 on Tuesday. The stock has a market cap of $3.06 billion, a PE ratio of 33.35, a price-to-earnings-growth ratio of 1.36 and a beta of 0.55. The business has a fifty day simple moving average of $59.12 and a 200-day simple moving average of $67.37. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. Haemonetics has a 12 month low of $47.31 and a 12 month high of $87.32.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, topping the consensus estimate of $1.28 by $0.01. The business had revenue of $346.35 million during the quarter, compared to analysts’ expectations of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.Haemonetics’s revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.24 earnings per share. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS.

Hedge Funds Weigh In On Haemonetics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Haemonetics by 3.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock valued at $1,877,000 after purchasing an additional 971 shares in the last quarter. Caxton Associates LLP acquired a new stake in Haemonetics during the first quarter valued at approximately $216,000. United Services Automobile Association acquired a new stake in Haemonetics during the first quarter valued at approximately $212,000. Empowered Funds LLC boosted its holdings in Haemonetics by 9.1% during the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock valued at $283,000 after purchasing an additional 372 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Haemonetics by 6.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock valued at $9,923,000 after purchasing an additional 9,051 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.